Abstract:e21646 Background: Identifying targetable genetic variants may help maximize clinical benefit of non-small cell lung cancer (NSCLC). Here, we retrospectively analyzed the benefit of next-generation sequencing (NGS) for NSCLC in routine clinical practice. Methods: A total of 59 NSCLC patients were enrolled in the study from Jun. 2018 to Dec. 2019. Formalin-fixed paraffin-embedded tissues samples were collected and sequenced by NGS, which detects single-nucleotide variants, small insertions/deletions, rearrangements, and copy-number alterations of either 59 or 1021 tumor related genes. The tumor response was evaluated using RECIST v1.1. Results: The detection rate of targetable variants was 59.32% (35/59), including EGFR mutation 49.15% (29/59), ALK rearrangement 5.08% (3/59), ROS1 rearrangement 1.69% (1/59), BRAF V600E mutation 1.69% (1/59), and ERBB2 mutation 1.69% (1/59). Of 29 patients with EGFR mutations, 5 patients (17.24%) had multiple EGFR mutations, including 2 patients (6.89%) with uncommon mutations. 25patients (86.21%) harbored concurrent mutations that may limit the efficacy of EGFR-TKIs, including EGFR amplification, activation of bypass signaling pathways, TP53 exon8 mutation, BCL2L11 deletion polymorphism, and PI3K-AKT-mTOR and cell cycle gene alterations. Among 25 patients received EGFR-TKIs, TKI effectiveness was evaluated in 18 patients. The disease control rate was 100% and overall response rate was 27.78%. The proportion of patients with TMB-H and/or PD-L1≥1, and targetable variants negative was 33.89% (20/59). Only one patient of this group received immunotherapy with pembrolizumab and achieved SD at the 2 nd month. The proportion of patients with targetable variants negative, TMB-L, and PD-L1 < 1 or unknow patients was 6.78% (4/59), two patients of them left hospital without additional treatment, two patients received chemotherapy and the KRAS mutation present in one of them suggested that he might be resistant to EGFR-TKIs. Conclusions: More than half of NSCLC patients have targetable genetic variants and more than 30% patients have a molecular signature that can be treated with immunotherapy. Compared with immunotherapy, targeted therapy has higher acceptability in real-world. NGS-based genetic testing may have clinical value to predict the effectiveness of targeted therapy and immunotherapy. It can be widely implemented and standardized into clinical use.

Prognostic Role of FGFR1 Amplification in Early-Stage Non-Small Cell Lung Cancer

Irreversible Inhibition of Nuclear Exoribonuclease by Thymidine-3'-Fluorophosphate and p-Haloacetamidophenyl Nucleotides

The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.

The Role of FGFR1 Gene Amplification As a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.

FGF19 Genetic Amplification As a Potential Therapeutic Target in Lung Squamous Cell Carcinomas.

FGFR1 Amplification and EGFR Mutation in Chinese Squamous Cell Lung Cancer.

Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis.

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

High Amplification of FGFR1 Gene is a Delayed Poor Prognostic Factor in Early Stage ESCC Patients

Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis

FGFR Genes Mutation is an Independent Prognostic Factor and Associated with Lymph Node Metastasis in Squamous Non-Small Cell Lung Cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Prognostic Value of Fgfr1 Overexpression and Amplification in Esophageal Squamous Cell Carcinoma Patients: A Combined Analysis from Tcga Database

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Functional Flt1 Genetic Variation is A Prognostic Factor for Recurrence in Stage I-Iii Non-Small-Cell Lung Cancer

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients

Programmed Cell Death‐ligand 1 (PD‐L1) Expression and Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification in Stage III/IV Lung Squamous Cell Carcinoma (SQC)

Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.